FDA has lifted the clinical hold on Intellia’s Phase 3 MAGNITUDE trial of nexiguran ziclumeran in ATTR-CM after a Grade 4 transaminase elevation with hyperbilirubinemia triggered a pause in October 2025. Enrollment will resume under amended protocols that add intensified liver lab monitoring in the early post-dose period, guidance for short-term steroid use if elevations occur, and stricter exclusion criteria, including recent cardiovascular instability and ejection fraction below 25% for the cardiomyopathy cohort. A separate January clearance restored enrollment in the smaller MAGNITUDE-2 study for hereditary ATTR with polyneuropathy under the same hepatic risk-mitigation framework.
The core development resumes a pivotal program built around a single 55 mg infusion of an in vivo CRISPR therapy designed to knock down TTR at the gene level. MAGNITUDE targets approximately 1,200 patients with ATTR-CM in a 2:1 randomization against placebo, with a composite cardiovascular events endpoint that includes mortality. MAGNITUDE-2 enrolls about 60 ATTRv-PN patients 1:1 versus placebo and reads out on change in modified neuropathy impairment score alongside serum TTR reduction. The asset holds U.S. Orphan and RMAT designations, with Orphan status in the EU, and reflects one of the most advanced systemic CRISPR programs now attempting to scale from small early studies to global, event-driven Phase 3 execution.
Strategically, the amended protocols reflect a balance between preserving broad access and insulating the program from recurrence of dose-related hepatic signals seen in first-in-class modalities. The added cardiovascular exclusions in MAGNITUDE are notable. They de-risk near-term safety optics but may lower event rates in a study already powered on hard outcomes, potentially stretching timelines and cost if accrual or event density softens. The steroid guidance and intensified early lab surveillance also acknowledge innate immune dynamics with LNP-delivered editing agents and formalize a playbook regulators are likely to expect across future in vivo programs.
For sites, the restart comes with operational friction. Teams will need rapid ethics re-approval, re-consent for amended risk language, tighter LFT schedules in the immediate post-infusion window, and ready access to short-course steroids under prespecified triggers. Cardiology sites may see a narrower eligible pool as EF and recent instability screens trim the sickest patients, complicating recruitment but aligning with safety guardrails. CROs will be pressed to recalibrate monitoring plans and data flow to capture transient hepatic signals in near real time. For sponsors across the field, the resolution offers a template: hepatic surveillance, steroid contingency, and targeted exclusions can get systemic CRISPR programs back on track after high-grade lab abnormalities.
The competitive context remains sharp. A one-time editing approach, if it sustains safety and delivers outcome benefits atop or instead of stabilizers, would challenge chronic RNAi and antisense regimens in both ATTR-CM and ATTRv-PN. Yet MAGNITUDE’s event-driven design means the definitive signal will take time, and the revised eligibility could dilute event accrual. Watch for updated safety incidence after enrollment restarts, clarity on background standard-of-care use and stratification, and any shifts to sample size or follow-up to maintain power. If the hepatic mitigation holds and early post-dose management proves operationally clean at scale, this program could set a regulatory and operational blueprint for systemic gene editing. If not, a second safety interruption would ripple beyond ATTR, tightening expectations for all late-stage in vivo CRISPR trials.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
